HKSA secara In-Silico Senyawa 1-Benzil-3- Benzoilurea dan Analognya sebagai Penghambat Reseptor Bruton Tyrosine Kinase (BTK)
DOI:
Abstract Views:
1061 times
PDF Downloads:
1425 times
Abstract
Abstract—In this study, a new anticancer drug design for non-Hodgkin’s lymphoma was carried out, with a molecular docking approach from the compound 1-benzyl-3-benzoylurea parent and its analog as an anticancer compound. The purpose of the study was to obtain the best quantitative structure-activity relationship (QSAR). The in-silico activity test was carried out on the new 1-benzyl-3-benzoilurea and its analog compound against the Bruton Tyrosine Kinase receptor (BTK) PDB code (5FBN) by using the Molegro Virtual Docker 5.5 program and producing a RS (Rerank Score) value for the test compound and Acalabrutinib was used as a comparison. This study also conducted bioavailability by predicting the value of F (intestinal human absorption) in the pkCSM program and toxicity studies by predicting LD50 values using the Protox II program. Correlation and regression were performed using the RS, F, and LD50 values that we obtained on the physicochemical properties of the test compound using the IBM SPSS version 24 program. The best equation is obtained as follows: (1) F = 0.851 Es Taft - 6.116 σ - 1.969 π² + 3.620 π + 90.809; (2) RS = 4.376 Es Taft - 88.802; (3) LD50 = 672.518 CMR - 669.385 ClogP - 813.806. From the results of the best equation is obtained that the activity is influenced by the parameters of steric physicochemical properties (Es Taft).
Keywords: 1-benzyl-3-benzoylurea, code pdb:5fbn, in-silico, non-hodgkin lymphoma
Abstrak—Pada penelitian ini dilakukan rancangan obat baru antikanker Limfoma non-Hodgkin, dengan pendekatan penambatan molekul dari senyawa induk 1-benzil-3-benzoilurea dan analognya sebagai senyawa antikanker.Tujuan penelitian ini untuk mendapatkan persamaan hubungan struktur aktivitas (HKSA) terbaik. Uji aktivitas in-silico dilakukan terhadap senyawa baru 1-benzil-3-benzoilurea dan analognya terhadap reseptor Bruton Tyrosine Kinase (BTK) kode PDB 5FBN dengan menggunakkan program Molegro Virtual Docker 5.5 dan menghasilkan nilai RS (Rerank Score) untuk senyawa uji dan Acalabrutinib digunakan sebagai pembanding. Penelitian ini juga dilakukan studi bioavaibilitas dengan memprediksi nilai F (intestinal human absorbtion) pada program pkCSM dan studi toksisitas dengan memprediksi nilai LD50 menggunakan program Protox II. Korelasi dan regresi dilakukan menggunakan nilai RS, F dan LD50 yang telah diperoleh terhadap parameter sifat fisikokimia senyawa uji menggunakan program IBM SPSS versi 24. Persamaan terbaik yang diperoleh sebagai berikut: (1) F = - 1.969 π² + 0.851 Es Taft - 6.116 σ + 3.620 π + 90.809 (2) RS = 4.376 Es Taft - 88.802 (3) LD50 = 672.518 CMR - 669.385 ClogP - 813.806. Dari hasil persamaan terbaik tersebut diperoleh bahwa aktivitas dipengaruhi oleh parameter sifat fisikokimia sterik (Es Taft).
Kata kunci: 1-benzil-3-benzoilurea, in-silico, kode pdb: 5fbn, limfoma non-hodgkin
Downloads
References
American Cancer Society. (2017). Lymphoma Cancer.
Anwar, A. D., Harsono, A. B., Sasotya, R. S., Amarullah, M. N., & Hidayat, D. (2013).
Bandung Controversies and Consensus in Obstetrics & Gynecology.
Arruebo, M., Villaboa, N., Saez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & Gonzalez-Fernandez, A. (2011). Assessment of the Evolution of Cancer Treatment Therapies. Cancers.
Astor, L. (2019, 11 21). FDA Approves Acalabrutinib for CLL/SLL. Retrieved from Targeted Oncology: https://www.targetedonc.com/news/fda-approves-acalabrutinib-for- cllsll
Drugbank. (2016, Oktober 20). Acalabrutinib. Retrieved Januari 10, 2020, from Drugbank: https://www.drugbank.ca/drugs/DB11703
Ferreira, L. G., Dos Santos, R., Olivia, G., & Andricopulo, A. (2015). Molecular Docking and Structure-Based Drug Design Strategies. Molecules, 13384-13421.
Kemenkes RI. (2015). Data dan Kondisi Penyakit Limfoma. InfoDATIN.
Globocan. (2018). Cancer Today. Retrieved September 2019, from International Agency for Research on Cancer: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
Koda-Kimble, M. A., Alldredge, B. K., Young, L. Y., Corelli, R. L., Guglielmo, B. J., Kradjan, W. A., & Williams, B. R. (2008). Applied Therapeutics The Clinical Use of Drugs.
National Cancer Institute. (2019, June 14). Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version. Retrieved July 2019, 26, from National Cancer Institute: https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment- pdq#_190
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Articles published in Keluwih: JKK are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to Kluwih: JKK to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in Keluwih: JKK, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.
